Evidence map›Paper›PMID 17566020›Full record

SynthesisGut2007

The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis.

Angelo Zullo, Vincenzo De Francesco, Cesare Hassan, Sergio Morini, Dino Vaira

3 registry-linked trialsAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Gut, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 89 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01273441 phase4completednot on this mapstarted 2010, after this paper: background citation

Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice

TypeinterventionalSponsorFundación de Investigación Biomédica - Hospital Universitario de La PrincesaRan2010 to 2012Enrolled338ConditionsHelicobacter PyloriArmsPPI, amoxicillin, metronidazole and clarithromycin
NCT01464060 phase4unknown statusnot on this mapstarted 2011, after this paper: background citation

Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance

TypeinterventionalSponsorInfante, Javier Molina, M.D.Ran2011 to 2013Enrolled400ConditionsHelicobacter Pylori InfectionArmsPPI, amoxicillin, metronidazole and clarithromycin
NCT02547038 nacompletednot on this mapstarted 2015, after this paper: background citation

Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication

TypeinterventionalSponsorKaohsiung Veterans General Hospital.Ran2015 to 2018Enrolled352ConditionsHelicobacter Pylori InfectionArmspantoprazole+bismuth+tetra+metro, (panto+amox+clar+metr)+(panto+amox)
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Helicobacter pylori and gastroduodenal ulcer disease.Deutsches Arzteblatt international · 2009
    Guideline
  10. Pooled it
  11. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Pooled it
  12. Trial
  13. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Angelo ZulloGastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital, Rome, Italy.
Vincenzo De Francesco
Cesare Hassan
Sergio Morini
Dino Vaira

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStandard triple therapies are the most used treatment in clinical practice. However, a critical fall in the H pylori eradication rate following these therapies has been observed in the last few years. The sequential regimen is a novel, promising therapeutic approach.

objectivesTo evaluate the available data on the sequential therapy regimen.

methodsA pooled-data analysis of all studies on the sequential regimen was performed. The eradication rate was calculated according to gastroduodenal pathology, proton pump inhibitor used, antibiotic resistance, as well as setting (paediatric or geriatric patients). Compliance, side effects, and cost implications were also evaluated.

resultsOverall, more than 1800 patients have been treated with the sequential regimen. Such a therapy was superior to 7-10 days triple therapies in paediatric, adult and elderly patients, achieving an eradication rate constantly higher than 90% at ITT analysis. Although primary clarithromycin resistance reduced the efficacy of such a therapy, a success rate significantly higher than that observed with the standard 7-10 days triple therapies was found.

conclusionThe 10-day sequential treatment regimen achieves higher eradication rates than standard triple therapies.

Indexed as

Helicobacter pyloriAdolescentAgedAged, 80 and overAge FactorsAnti-Bacterial AgentsAnti-Ulcer AgentsChildChild, PreschoolDrug Administration ScheduleDrug Therapy, CombinationHelicobacter InfectionsHumansProton Pump InhibitorsRandomized Controlled Trials as TopicTreatment OutcomeAnti-Bacterial AgentsAnti-Ulcer AgentsProton Pump Inhibitors

Identifiers

PMID17566020
PMCPMC2000235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.